Reproxalap is a reactive aldehyde species inhibitor. This article investigates reproxalap’s ability to control ocular inflammation in non-infectious uveitis, allergic conjunctivitis and dry eye disease. Clinical trials for reproxalap were reviewed for efficacy and tolerability. Reproxalap appears to be an effective treatment for dry eye disease, with satisfactory tolerability.
No takes yet. Share an insight, caveat, or question.
Tracy Schroeder Swartz (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: